Granted Patent B2

US 12,311,059 · App. 17/083,771 · Granted May 27, 2025

Inventors: Giovanni Mambrini (Mirandola, IT); Luca Benatti (Monza, IT); Giovanni Capogrossi (Jesi, IT); Marco Mandolini (Senigallia, IT)

Assignee: Quince Therapeutics S.p.A.

A61K9/5068A61K9/5089A61K31/661A61K35/18A61K38/45C12N5/0641C12Y207/01001

Abstract

Claims (20)

1. A method of treating a patient suffering from Ataxia telangiectasia, the method comprising:

(a) removing whole blood from the patient;

(b) using the whole blood, preparing a population of erythrocytes by

(i) isolating erythrocytes from the whole blood;

(ii) swelling the erythrocytes using a first hypotonic solution;

(iii) further swelling the erythrocytes in step (ii) with a second hypotonic solution that is more hypotonic that the first hypotonic solution, wherein the further swelling is done without reaching lysis;

(iv) concentrating the erythrocytes obtained in step (iii);

(v) placing the concentrated erythrocytes in contact with a lysing solution comprising one or more pharmaceutical products for treating Ataxia telangiectasia; and

(vi) adding a sealing solution for the purpose of obtaining a population of erythrocytes loaded with said one or more pharmaceutical products; and

(c) injecting the population of erythrocytes into the patient.

2. The method of claim 1 , wherein about 50 mL of the whole blood is removed from the patient.

3. The method of claim 1 , wherein the treatment is repeated monthly.

4. A method of treating ataxia telangiectasia in a patient in need thereof, comprising administering a therapeutically effective dose of erythrocytes encapsulated with dexamethasone sodium phosphate (DSP) to the patient, wherein the dose is prepared by:

(d) obtaining between 20-100 mL of whole blood of the patient;

(e) separating erythrocytes from the whole blood;

(f) swelling the erythrocytes using a first hypotonic saline solution having an osmolality between 230 and 150 mOsm/kg;

(g) further swelling the erythrocytes using a second hypotonic solution having a lower osmolality than the first hypotonic saline solution, wherein the further swelling is done without reaching lysis, thereby providing swollen erythrocytes;

(h) contacting the swollen erythrocytes with a solution comprising between 2-10 mL of a solution comprising dexamethasone sodium phosphate at a concentration of 25 mg/mL; and

(i) incubating the swollen erythrocytes with a hypertonic sealing solution comprising phosphate-inosine-glucose-pyruvate-adenine (PIGPA).

5. The method of claim 4 , wherein the erythrocytes convert DSP to dexamethasone which is released into the patient's circulation.

Assignments (4)

Priority Claims (2)

Continuity (2)

References Cited (24)